That any one of three signaling pathways can maintain expression of these proteins in the face of the drug combination argues that it is the ability of [ruxolitinib + MMF] to simultaneously inhibit the STAT3, AKT and MEK-ERK pathways which is crucial in promoting tumor cell killing. The gene discussed is STAT3; the disease is neoplasm.